Brain metastases affect 37% of patients suffering from metastatic
melanoma, and their prognosis remains poor, with an overall survival lower than six months. At the moment, there is no standard therapeutic strategy for management of
melanoma brain metastases. In some cases, having recourse to a systemic treatment is justified, for example, when
brain metastases are combined with a progressive peripheral disease, or with unresecable brain lesions. In France, the use of
fotemustine, which received the AMM approval, for metastatic
melanoma treatment, is one of the treatments recommended in the case of
brain metastases as this
chemotherapy, that is active on the
melanoma passes the blood-brain barrier.
Temozolomide also shows some activity in the
brain metastases treatment of
melanoma that remains modest in monotherapy but seems interesting when it is combined with
radiotherapy. The place of new drugs, in particular
ipilimumab and
vemurafenib, in the strategy of
melanoma brain metastases treatment, still has to be defined and may improve the prognosis of these patients and their quality of life. The new targeted
therapies, the widespread use of stereotactic radiosurgery and the improvement in neurosurgical operations would need a prospective clinical assessment, all the more so, in most of clinical studies, the presence of
metastases is an exclusion criterion.